银屑病患者使用阿维A与改善病情抗风湿药相比的银屑病关节炎风险:全国性队列研究
该回顾性队列研究利用台湾全民健康保险研究数据库(1997–2013年),比较银屑病患者使用阿维A或改善病情抗风湿药(DMARDs)后银屑病关节炎(PsA)的风险。两队列各纳入1948例患者,阿维A队列5年PsA累积发生率低于DMARDs队列(7.52% vs 9.93%,P=0.005),但校正后阿维A与PsA发生无显著关联(HR 0.83,95%CI 0.65–1.05)。结论认为与DMARDs相比,阿维A不增加银屑病患者PsA风险。
要点
- 阿维A队列5年PsA累积发生率为7.52%,低于DMARDs队列的9.93%(P=0.005)。
- 校正混杂因素后,阿维A与PsA发生无显著关联(HR 0.83,95%CI 0.65–1.05)。
- 女性及使用NSAIDs是PsA的其他独立危险因素。
核心结论
- 与DMARDs相比,阿维A不增加银屑病患者发生PsA的风险。
研究设计与样本
- 回顾性队列研究,使用台湾全民健康保险研究数据库1997至2013年数据。
- 成年银屑病无PsA患者,按一年内使用阿维A或DMARDs≥30天分别归入阿维A队列或DMARDs队列。
- 阿维A队列中使用DMARDs>7天者、或DMARDs队列中使用阿维A>7天者被排除。
- 两队列各纳入1948例患者。
主要发现
- 阿维A队列5年PsA累积发生率为7.52%,DMARDs队列为9.93%(P=0.005)。
- 在接受NSAIDs治疗的亚组中,两队列差异更明显。
- 在未接受NSAIDs治疗的亚组中,阿维A队列5年PsA累积发生率为5.26%,DMARDs队列为6.98%(P=0.106)。
- 阿维A与PsA发生无显著关联(HR 0.83,95%CI 0.65–1.05),校正NSAIDs治疗和合并症后结果一致。
- 其他独立危险因素包括女性和NSAIDs治疗。
关键数值与推荐
- 阿维A队列5年PsA累积发生率为7.52%,DMARDs队列为9.93%(P=0.005)。
- 未接受NSAIDs亚组中,阿维A队列5年PsA累积发生率为5.26%,DMARDs队列为6.98%(P=0.106)。
- 阿维A与PsA发生的HR为0.83(95%CI 0.65–1.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare the risk of PsA in psoriasis (PsO) patients treated with acitretin vs DMARDs. METHODS: This retrospective study used Taiwan's National Health Insurance Research Database from 1997 to 2013. Adult PsO patients without PsA prescribed acitretin or DMARDs for ≥30 days within a year were assigned to the acitretin cohort or DMARDs cohort, respectively. Patients in the acitretin cohort prescribed DMARDs for >7 days, or in the DMARDs cohort prescribed acitretin for >7 days, were excluded. Cumulative incidence of PsA were determined within both cohorts using the Kaplan-Meier method. The hazard ratio (HR) comparing acitretin to DMARDs was calculated with Cox regression models, adjusting for demographic and clinical covariates including the use of NSAIDs and comorbidities. RESULTS: The study included 1948 patients in each cohort. The 5-year cumulative incidence of PsA in the acitretin cohort was lower than that in the reference cohort (7.52% vs 9.93%; P = 0.005), with a more pronounced difference in the subpopulation receiving NSAIDs treatment. However, in subpopulations without NSAIDs treatment, the 5-year cumulative incidence of PsA in the acitretin cohort was comparable to the DMARDs cohort (5.26% vs 6.98%; P = 0.106). Acitretin was not associated with PsA development in PsO (HR 0.83, 95% confidence interval 0.65-1.05). This risk remained consistent regardless of adjustments for NSAID treatment and comorbidities. Other independent risk factors for PsA included female and NSAIDs treatment. CONCLUSION: Compared with DMARDs, acitretin was not associated with increased PsA risk in PsO patients.
引用
- Lin TL, Chang YL, Ho HJ, et al. Psoriatic arthritis risk in psoriasis patients prescribed acitretin versus disease-modifying antirheumatic drugs: a nationwide cohort study. Rheumatology (Oxford). 2024. PMID: 37656926. doi:10.1093/rheumatology/kead446
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。